Volume | 14,521 |
|
|||||
News | - | ||||||
Day High | 9.25 | Low High |
|||||
Day Low | 8.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Oncternal Therapeutics Inc | ONCT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.04 | 8.00 | 9.25 | 9.00 | 8.20 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
265 | 14,521 | $ 8.51 | $ 123,546 | - | 5.22 - 16.60 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:37:58 | 10 | $ 9.00 | USD |
Oncternal Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
27.2M | 2.96M | - | 785k | -39.48M | -13.34 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Oncternal Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.19 | 9.25 | 7.81 | 8.11 | 3,652 | 0.81 | 9.89% |
1 Month | 9.35 | 10.613 | 7.4819 | 9.02 | 9,522 | -0.35 | -3.74% |
3 Months | 9.60 | 10.613 | 5.5656 | 7.64 | 43,336 | -0.60 | -6.25% |
6 Months | 6.198 | 13.14 | 5.5656 | 8.17 | 151,069 | 2.80 | 45.21% |
1 Year | 15.472 | 16.60 | 5.22 | 7.51 | 259,430 | -6.47 | -41.83% |
3 Years | 155.00 | 211.20 | 5.22 | 57.88 | 517,164 | -146.00 | -94.19% |
5 Years | 137.40 | 211.20 | 5.22 | 76.49 | 679,348 | -128.40 | -93.45% |
Oncternal Therapeutics Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. |